Skip Navigation

Cardiovascular Research 1998 37(1):34-41; doi:10.1016/S0008-6363(97)00194-6
© 1998 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Schlüter, K.-D.
Right arrow Articles by Piper, H. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schlüter, K.-D.
Right arrow Articles by Piper, H. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1998, European Society of Cardiology

Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide

Klaus-Dieter Schlüter* and Hans Michael Piper

Physiologisches Institut, Justus-Liebig-Universität Giessen, Aulweg 129, D-35392 Giesen, Germany

* Corresponding author. Tel.: (+49-641) 9947243; Fax: (+49-641) 9947239; E-mail: klaus-dieter.schlueter@physiologie.med.uni-giessen.de

Cardiovascular cells (cardiomyocytes and smooth muscle cells) are target cells for parathyroid hormone (PTH) and the structurally related peptide parathyroid hormone-related peptide (PTH-rP). PTH activates protein kinase C (PKC) of cardiomyocytes via a PKC activating domain previously identified on chondrocytes. Activation of PKC leads to hypertrophic growth and re-expression of fetal type proteins in cardiomyocytes. This hypertrophic effect of PTH might contribute to left ventricular hypertrophy in hemodialysis patients with secondary hyperparathyroidism. PTH-rP is expressed in cardiovascular cells (endothelial cells and smooth muscle cells). It does not mimic the above described actions of PTH but exerts effects of its own on cardiomyocytes. These effects involve activation of protein kinase A, via a N-terminal domain distinct from that identified on PTH, and activation of PKC, via a C-terminally located domain distinct from that found on PTH. On smooth muscle cells PTH and PTH-rP reduce the influence of extracellular calcium, through cAMP-dependent mechanisms. These inhibitory effects on voltage-dependent L-type calcium channels of smooth muscle cells cause vasorelaxation. Present studies concerning cardiovascular actions of either PTH and PTH-rP suggest that increased plasma levels of PTH and PTH-rP influence cardiomyocyte and smooth muscle cell physiology. It can be assumed that PTH-rP acts as a paracrine or autocrine modulator in heart and vessels.

KEYWORDS Hormones; Hypertrophy; Myocytes; Smooth muscle; Vasoactive agents


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
N. Ono, K. Nakashima, S. R. Rittling, E. Schipani, T. Hayata, K. Soma, D. T. Denhardt, H. M. Kronenberg, Y. Ezura, and M. Noda
Osteopontin Negatively Regulates Parathyroid Hormone Receptor Signaling in Osteoblasts
J. Biol. Chem., July 11, 2008; 283(28): 19400 - 19409.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
K.-D. Schluter, R. Schreckenberg, and S. Wenzel
Stem cell mobilization versus stem cell homing: potential role for parathyroid hormone?
Cardiovasc Res, March 1, 2008; 77(4): 612 - 613.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.